tVNS for depression

The short version

If you or someone you care for has depression that has not responded well enough to medication, tVNS is worth knowing about. It is a small device with an electrode worn in the ear that delivers gentle electrical pulses to a branch of the vagus nerve. The goal is to improve mood, and the evidence suggests it does so through the same brain pathways that antidepressants target, plus a few that they do not. It is used alongside your existing treatment, never as a replacement. You use it at home, for about an hour a day.

The tVNS device is a certified medical device with a specific regulatory approval for depression, manufactured in Germany and distributed in the UK by Anatomical Concepts UK. If you are curious whether it could help you, read on.

What we are trying to solve

Depression is common, serious, and often stubborn. In the UK, roughly one in six adults experiences depression at any given time. For the majority, antidepressant medication brings meaningful relief. But for around 30% of people with major depression, the drugs do not work well enough. Clinicians call this treatment-resistant depression, usually defined as a failure to respond to two or more adequate courses of antidepressant medication.

If you are in that group, you already know how frustrating it can be. You may have tried several medications, each with its own side effects: weight gain, emotional blunting, sexual dysfunction, fatigue. You may have been offered electroconvulsive therapy (ECT), which can be effective but requires general anaesthesia and carries cognitive side effects. You may have been referred for repetitive transcranial magnetic stimulation (rTMS), which requires daily clinic visits for weeks.

tVNS is a different kind of option. It engages the brain's mood circuits through the vagus nerve, is self-administered at home, and builds its effect gradually over weeks. It is not a first-line treatment and it is not a miracle. It is a genuine option for people who have not been fully helped by the treatments they have already tried.

How it works, in plain English

The vagus nerve connects the brainstem to the heart, lungs, gut, and immune system. A small branch of it, the auricular branch, surfaces in the outer ear on a ridge called the cymba conchae.

The tVNS device clips into the ear and touches this ridge. When you switch it on, it sends gentle electrical pulses into that branch. Those pulses travel up to the brainstem and from there to brain regions that are directly involved in depression.

Two of those regions matter most.

The locus coeruleus, which produces norepinephrine. This is the same system that SNRIs (a class of antidepressant) are designed to boost.
The raphe nuclei, which produce serotonin. This is the same system that SSRIs target.

A head-to-head study comparing tVNS with citalopram (a common SSRI) found that both treatments increased levels of serotonin, dopamine, GABA, and noradrenaline in the blood, with no significant difference between the two groups. In other words, tVNS appears to engage the same neurotransmitter systems as conventional antidepressants.

But it also does things that drugs do not. It reduces inflammation through a pathway called the cholinergic anti-inflammatory reflex. It promotes the production of BDNF, a protein that supports the brain's ability to form new connections. And brain imaging studies show that it shifts the patterns of brain activity that are characteristically disrupted in depression.

None of this happens overnight. The brain adapts gradually. This is why tVNS asks for patience, and why most studies show the clearest benefit after eight to twelve weeks of consistent daily use.

What the evidence shows

tVNS is not a cure for depression. But the evidence now supports its use as an adjunctive treatment, and the picture has been strengthening over the last few years.

In the largest pilot study, 160 people with major depression used tVNS at home for up to 12 weeks. At 4 weeks, 27% had responded. By 8 weeks, 53% had responded. By 12 weeks, 80% had responded, and 39% had achieved remission.
In a head-to-head comparison with citalopram (107 patients), tVNS produced comparable improvements in depression scores, with tVNS actually achieving higher remission rates at weeks 4 and 6.
A meta-analysis of 12 randomised trials (838 participants) found that tVNS significantly improved depression scores and achieved higher response rates than sham stimulation.
The long-term picture from implanted vagus nerve stimulation (the surgical version of the same idea) is also encouraging: a five-year study showed a 67.6% response rate, compared with 40.9% for treatment as usual.

It is worth saying clearly: the evidence for tVNS in depression is encouraging but not yet definitive. The largest studies come from Chinese populations, and large sham-controlled trials in Western populations are still needed. The quality of the evidence, by strict academic standards, is rated as low to moderate. We think the honest framing is this: the signals are real, the mechanism is well understood, and the safety profile is excellent, but the field is still building the kind of large, rigorous evidence base that will satisfy every sceptic.

What to expect

Here is what a typical tVNS treatment for depression looks like in practice.

You keep taking your current medication. tVNS is an add-on, not a replacement. Any medication changes should be discussed with your prescribing clinician.
You use the device at home, typically for 30 minutes twice a day, though your clinician may suggest a different schedule.
You keep a mood diary. This does not need to be complicated. A daily note on how you feel, rated on a simple scale, gives you and your clinician the information you need.
You wait, and you persist. The first signs of benefit often appear around four weeks, but the clearest improvements tend to come at eight to twelve weeks. This is not unusual for neuromodulation: the brain changes slowly.
You review with your clinician. At four, eight, and twelve weeks, sit down with your doctor and look at the diary together. If the device is working, you continue. If not, you and your clinician decide what to try next.

A note on the time course. The response pattern in depression is similar to what we see in epilepsy: it builds. The 80% response rate at twelve weeks in the largest study started at 27% at four weeks. This means the first month can feel discouraging, even if the treatment is ultimately going to work. We make this point clearly because managing expectations is one of the most important things we can do.

Who it is not for

tVNS is intended for adults aged 18 and over, and it is generally well tolerated, but there are some situations where it is not suitable. Do not use tVNS if you:

are pregnant
have an active implant, such as a cochlear implant, an implanted vagus nerve stimulator, or a cardiac pacemaker
have a cerebral shunt (for example, for hydrocephalus)
have sore or broken skin where the electrode would sit

If you have a heart rhythm problem, talk to your doctor before using tVNS. As with any vagus nerve therapy, a few people notice a temporary dip in mood early on. tVNS should be used under medical supervision. If you have any doubt, ask your clinician or ask us.

Common questions

Is tVNS the same as ECT? No. ECT passes an electrical current through the brain under general anaesthesia to induce a brief seizure. It is a powerful treatment but carries cognitive side effects. tVNS delivers gentle pulses to a nerve in the ear, at home, with no anaesthesia and no seizure. They are very different approaches.

Can I stop my antidepressant if I start tVNS? That is a decision for you and your prescribing clinician, not for us. tVNS is designed to be used alongside medication, not as a replacement. Some people do reduce their medication over time, but this should always be done under clinical supervision.

How does it compare with rTMS? rTMS (repetitive transcranial magnetic stimulation) is another non-invasive neuromodulation approach for depression. It requires daily visits to a specialist clinic for four to six weeks. tVNS is used at home. No head-to-head trials exist comparing the two, so we cannot say definitively which is more effective. The practical difference is accessibility: tVNS fits into your daily life without requiring clinic visits.

What does it feel like? A gentle tingling in the ear. It should be noticeable but comfortable, never painful. The intensity is set just below your pain threshold.

Will my GP prescribe it? You do not need a prescription to buy tVNS, but its Instructions for Use state that it should be used under medical supervision, so we strongly recommend agreeing it with your clinician before you start. If your GP or psychiatrist wants more information, we are happy to speak to them.

How much does it cost? Considerably less than implanted VNS, rTMS, or ongoing CGRP medication. You can find current pricing on the device page. If cost is a barrier, contact us and we can talk through options.

What to do next

If you are considering tVNS for depression, here are three sensible next steps.

Talk to your psychiatrist, GP, or specialist. Ask whether they are open to neuromodulation as an add-on to your current treatment. If they want more information, we can speak to them directly.
Read the clinicians' page if you want a deeper dive into the evidence, the dosing parameters, and the mechanisms. It is written for healthcare professionals but the curious and determined reader often gets a lot from it too.
Contact us. If you have specific questions about whether tVNS might be right for you, call or email. We will give you a straight answer, including whether we think tVNS is unlikely to help in your situation.

Contact Anatomical Concepts UK

For clinicians: the full evidence page

How to access tVNS

This page is for information only. It is not medical advice. Any decision about tVNS should be made with your clinician, who knows your full medical history.

tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.